

**Rabbit Anti-B7-H4 [B7H4/2652R]: RM0309, RM0309RTU7**

**Intended Use:** For Research Use Only

**Description:** T cell activation and immune function are regulated by the innate immune system through positive and negative costimulatory proteins. One such protein, B7-H4 (B7-homolog 4), belongs to the B7 immunoglobulin superfamily of ligand-lymphocyte interacting proteins. Expressed primarily on the membrane of lymphoid cells, B7-H4 is an immuno-inhibitory protein that interacts with receptors on the surface of T lymphocytes, thus mediating cellular and humoral immune responses. Overexpression of the B7-H4 protein is associated with certain malignancies, including ovarian and breast cancer, as its interaction with T cells suppresses tumor-associated immunity. Current research suggests that, similar to Mucin 16 (CA-125), B7-H4 may be a useful biomarker for the early detection of ovarian cancer.

**Specifications**


Clone:	B7-H4
Source:	Rabbit
Isotype:	IgG
Reactivity:	Human
Immunogen:	Human B7-H4 protein recombinant fragment
Localization:	Membrane, cytoplasm
Formulation:	Purified antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC, ELISA, Flow Cyt., IF
Package:	

Description	Catalog No.	Size
B7-H4 Concentrated	RM0309	1 ml
B7-H4 Prediluted	RM0309RTU7	7 ml

**IHC Procedure**

Positive Control:	Ovary, pancreas, placenta, spleen, HeLa or MCF-7 cells
Concentrated Dilution:	50-200
Pretreatment:	Tris EDTA pH9.0, 15 minutes Pressure Cooker or 30-60 minutes water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

\* Result should be confirmed by an established diagnostic procedure.



FFPE human testicular carcinoma stained with anti-B7-H4 using DAB

**References:**

1. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration. Kim GE et al. Tumour Biol. 2018.
2. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Bregar A et al. Gynecol Oncol. 2017.
3. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Leong SR et al. Mol Pharm. 2015.

Doc. 100-RM0309  
Rev. A